SLC5A2 and type 2 diabetes mellitus: In people aged ≥ 60 years with type 2 diabetes, SGLT2 inhibitor versus DPP4 inhibitor initiation was associated with lower risk of all-cause dementia, and the observed risk reduction was greater with continuous use.